Royalty Pharma (RPRX) Stock Valuation After 11% Revenue Growth And US$1.25b In New Royalty Deals

Royalty Pharma (RPRX) has attracted fresh attention after reporting 11% year on year revenue growth while falling short of analyst forecasts, alongside announcing up to US$1.25b in new royalty transactions in the first quarter.

See our latest analysis for Royalty Pharma.

Despite the recent revenue miss, the stock has been strong, with the share price up 17.70% over 90 days and a 57.93% total shareholder return over the past year. This suggests momentum is building even as insiders have been net sellers and the boardroom sees some change.

If this kind of deal driven growth story has your attention, it can be useful to scan other opportunities and see how they compare using the 39 healthcare AI stocks

With the stock up strongly over the past year and trading close to analyst price targets, yet with a large implied intrinsic discount and a growing royalty portfolio, the key question is simple: is there still an opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 8.4% Undervalued

Compared to the last close at $54.27, the most followed narrative points to a fair value of $59.25, framing Royalty Pharma as modestly undervalued on long term cash flows.

The robust scientific pipeline, driven by advancements in biologics, gene therapies, and next-generation medicines like daraxonrasib, creates high-value assets that can enter into blockbuster status. Participation in these early, high-impact assets (as in the Revolution Medicines deal) positions Royalty Pharma for long-duration, high-growth royalty streams, directly benefitting long-term revenue and earnings.

Read the complete narrative.

Analysts behind this narrative are leaning on a powerful mix of faster revenue expansion, sharply higher margins, and an earnings profile that supports a lower future P/E. Curious which assumptions really move that $59.25 fair value and how they connect to the current $54.27 share price? The full narrative lays out the numbers that underpin that gap.

Result: Fair Value of $59.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the royalty dispute over Alyftrek and rising competition for drug finance deals could still pressure future cash flows and challenge those optimistic valuation assumptions.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment split between fresh royalty growth and live disputes, it makes sense to look at the data yourself and act while the information is clear. To weigh up both sides of the story in one place, start with the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you only focus on Royalty Pharma, you could miss other stocks that fit your style, so use screeners to widen your opportunity set with purpose.

• Target potential turnaround stories with tighter risk filters by scanning 23 elite penny stocks with strong financials that already show stronger financial footing than most low priced stocks.
• Hunt for quality companies trading at attractive valuations by using the 47 high quality undervalued stocks and lining them up against your own return and risk expectations.
• Prioritise resilience by checking the 68 resilient stocks with low risk scores that combine sturdier balance sheets with business profiles designed to handle more than one market cycle.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com